"10.1371_journal.pone.0040439","plos one","2012-07-10T00:00:00Z","Alan L Ho; Elgilda Musi; Grazia Ambrosini; Jayasree S Nair; Shyamprasad Deraje Vasudeva; Elisa de Stanchina; Gary K Schwartz","Laboratory of New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America; Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America; Department of Medicine, Weill Medical College of Cornell University, Ithaca, New York, United States of America","Conceived and designed the experiments: ALH EM SDV EDS GKS. Performed the experiments: ALH EM SDV EDS. Analyzed the data: ALH EM GA JSN SDV EDS GKS. Contributed reagents/materials/analysis tools: GA JSN EDS. Wrote the paper: ALH EM GKS.","The authors have read the journals policy and have the following conflicts: one-time paid consultancy (AstraZeneca), research funding (AstraZeneca) was provided to Alan Ho. To clarify, funding in both instances were not used or applicable to the study described in this submission, but instead to other, unrelated clinical research. Selumetinib and AZD8055 were supplied by AstraZeneca for this study. There are no other patents, products in development or other marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","07","Alan L Ho","ALH",7,TRUE,5,4,7,3,TRUE,TRUE,FALSE,0,NA,FALSE
